Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Pagoda Biopharma-B (02565) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Pagoda Biopharma is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Pagoda Biopharma previously announced that all conditions of the placement agreement had been met, with the placement completed on December 22, 2025 [1] - Under the terms of the placement agreement, the joint placement agents sold a total of 5.136 million shares at a price of HKD 58.41 per share to no fewer than six subscribers, representing approximately 1.81% of the enlarged H-shares and about 1.31% of the total shares after the placement [1]
派格生物医药-B获纳入恒生综合指数 有望成为港股通标的